Gyre Therapeutics, Inc. (GYRE)
NASDAQ: GYRE · Real-Time Price · USD
12.91
-0.01 (-0.08%)
Nov 20, 2024, 4:00 PM EST - Market closed
Gyre Therapeutics Employees
Gyre Therapeutics had 593 employees as of December 31, 2023.
Employees
593
Change
n/a
Growth
n/a
Revenue / Employee
$177,121
Profits / Employee
-$149,784
Market Cap
1.11B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 593 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Brookdale Senior Living | 36,000 |
| Aveanna Healthcare Holdings | 33,500 |
| The Pennant Group | 5,791 |
| Artivion | 1,500 |
| Phreesia | 1,438 |
| Establishment Labs Holdings | 908 |
| ANI Pharmaceuticals | 642 |
| Arcutis Biotherapeutics | 296 |
GYRE News
- 8 days ago - Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update - GlobeNewsWire
- 4 weeks ago - Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis - GlobeNewsWire
- 7 weeks ago - Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor Conference - GlobeNewsWire
- 3 months ago - Gyre Therapeutics Reports Second Quarter 2024 and Year-To-Date Financial Results and Provides Business Update - GlobeNewsWire
- 3 months ago - Gyre Therapeutics to Present at Sidoti Virtual Investor Conference - GlobeNewsWire
- 5 months ago - Gyre Therapeutics Announces China's NMPA Approval of Avatrombopag Maleate Tablets for the Treatment of CLD-Associated Thrombocytopenia - GlobeNewsWire
- 5 months ago - Gyre Therapeutics Announces Publication in Journal of Gastroenterology and Hepatology - GlobeNewsWire
- 6 months ago - Gyre Pharmaceuticals Receives IND Approval from China's NMPA to Evaluate F230 for the Treatment of Pulmonary Arterial Hypertension - GlobeNewsWire